A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (vol 26, pg 1547, 2015)

被引：55
作者：
Cherny, N. I.
Sullivan, R.
Dafni, U.
Kerst, J. M.
Sobrero, A.
Zielinski, C.
de Vries, E. G. E.
Piccart, M. J.
机构：
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 11期
关键词：
D O I：
10.1093/annonc/mdw258
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2901 / 2905
页数：5
相关论文
共 1 条
[1]   A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].
Cherny, N. I. ;
Sullivan, R. ;
Dafni, U. ;
Kerst, J. M. ;
Sobrero, A. ;
Zielinski, C. ;
de Vries, E. G. E. ;
Piccart, M. J. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573
1